Paclitaxel-Coated Balloons: Review of a Promising Interventional Approach to Preventing Restenosis in Femoropopliteal Arteries

International Journal of Angiology

Volumn 25, Issue 2, 2016, Pages 75-80

  Teleb, Mohamed ^a   Wardi, Miraie ^a   Gosavi, Sucheta ^a   Said, Sarmad ^a   Mukherjee, Debabrata ^a  

^a Paul L Foster School of Medicine   (United States)

Author keywords

angioplasty; atherosclerosis; claudication; critical limb ischemia; femoral artery; peripheral arterial disease

Indexed keywords

PACLITAXEL;

ANGIOPLASTY; BALLOON; CLINICAL EFFECTIVENESS; DRUG ELUTING BALLOON; DRUG ELUTING STENT; FEMOROPOPLITEAL ANGIOPLASTY; FEMOROPOPLITEAL ARTERY; HUMAN; INTERMETHOD COMPARISON; LATE LUMEN LESION; LESIONS AND DEFECTS; OUTCOME ASSESSMENT; PATIENT SAFETY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; REVIEW; TARGET LESION REVASCULARIZATION; TREATMENT RESPONSE;

EID: 84940993869     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0035-1563608     Document Type: Review

References (21)

1. Creager M. A., Belkin M., Bluth E. I., et al. 2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS Key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to develop Clinical Data Standards for peripheral atherosclerotic vascular disease). J Am Coll Cardiol: 2012; 59 3 294 357
2. Olin J. W., Sealove B. A. Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc: 2010; 85 7 678 692
3. Hirsch A. T., Haskal Z. J., Hertzer N. R., et al. American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol: 2006; 47 6 1239 1312
4. Ciccone M. M., Scicchitano P., Cameli M., Cecere A., Cortese F., et al. Endothelial function in pre-diabetes, diabetes and diabetic cardiomyopathy: a review. J Diabetes Metab: 2014; 5 364
5. Ciccone M. M., Marchese A., Generali A., et al. Interventional therapy in diabetic foot: risk factors, clinical events and prognosis at one year followup (a study of 103 cases). Pak J Biol Sci: 2012; 15 16 789 794
6. Wolfe J. H., Wyatt M. G. Critical and subcritical ischaemia. Eur J Vasc Endovasc Surg: 1997; 13 6 578 582
7. Vierron E., Halimi J. M., Giraudeau B. Ankle-brachial index and peripheral arterial disease. N Engl J Med: 2010; 362 5 471, author reply 471-472
8. Beebe H. G., Dawson D. L., Cutler B. S., et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med: 1999; 159 17 2041 2050
9. Lehert P., Comte S., Gamand S., Brown T. M. Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol: 1994; 23 03 S48 S52
10. Wolf G. L., Wilson S. E., Cross A. P., Deupree R. H., Stason W. B. Surgery or balloon angioplasty for peripheral vascular disease: a randomized clinical trial. Principal investigators and their Associates of Veterans Administration Cooperative Study Number 199. J Vasc Interv Radiol: 1993; 4 5 639 648
11. Simpson E. L., Michaels J. A., Thomas S. M., Cantrell A. J. Systematic review and meta-analysis of additional technologies to enhance angioplasty for infrainguinal peripheral arterial occlusive disease. Br J Surg: 2013; 100 9 1128 1137
12. Werk M., Albrecht T., Meyer D. R., et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv: 2012; 5 6 831 840
13. Werk M., Langner S., Reinkensmeier B., et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: Femoral Paclitaxel randomized pilot trial. Circulation: 2008; 118 13 1358 1365
14. Tepe G., Zeller T., Albrecht T., et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med: 2008; 358 7 689 699
15. Tepe G., Schnorr B., Albrecht T., et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv: 2015; 8 (1 Pt A): 102 108
16. Fanelli F., Cannavale A., Boatta E., et al. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovasc Ther: 2012; 19 5 571 580
17. Liistro F., Grotti S., Porto I., et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv: 2013; 6 12 1295 1302
18. Scheinert D., Duda S., Zeller T., et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv: 2014; 7 1 10 19
19. Efficacy Study of Stenting, Paclitaxel Eluting Balloon or Atherectomy to Treat Peripheral Artery Disease (ISAR-STATH). 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT00986752?term=nct00986752&rank=1
20. Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries (LEVANT 2). 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT01412541?term=nct01412541&rank=1
21. IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA) (INPACT SFA II). 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT01566461?term=nct01566461&rank=1